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Tumor necrosis factor a (TNFa) activates the stress-
activated protein kinases (SAPKs, also known as Jun
nuclear kinases or JNKs) resulting in the stimulation of
AP-1-dependent gene transcription and induces the
translocation of NFkB to the nucleus resulting in the stim-
ulation of NFkB-dependent gene transcription. A poten-
tial second messenger for these signaling pathways is ce-
ramide, which is generated when TNFa activates
sphingomyelinases. We show that treatment of HL-60 hu-
man promyelocytic cells with exogenous sphingomyelin-
ase leads to rapid stimulation of JNK/SAPK activity, an
effect not mimicked by treatment with phospholipase A2,
C, or D. Further, JNK/SAPK activity is stimulated 2.7- and
2.8-fold, respectively, in cells exposed to C2-ceramide (5
mM) or TNFa (10 ng/ml). The prolonged stimulation of this
kinase activity by C2-ceramide is similar to that previ-
ously reported for TNFa. In contrast, the relatedmitogen-
activated protein kinases ERK1 and ERK2 are weakly
stimulated following TNFa treatment (1.5-fold) and are
inhibited by C2-ceramide treatment. TNFa also potently
stimulates NF-kB DNA binding activity and transcrip-
tional activity, but these effects are not mimicked by ad-
dition of C2-ceramide or sphingomyelinase to intact
cells. Furthermore, TNFa, sphingomyelinase, and C2-ce-
ramide induce c-jun, a gene that is stimulated by the
ATF-2 and c-Jun transcription factors. These data sug-
gest that ceramide may act as a second messenger for a
subset of TNFa’s biochemical and biological effects.
TNFa1 is a multifunctional cytokine involved in inflamma-
tion, infection, and cancer (1, 2). TNFa has potent biological
effects on cultured cells, including induction of apoptosis and
differentiation (3, 4). TNFa signals via unknown second mes-
sengers leading to activation of NFkB (5, 6) and JNKs/SAPKs
(7–9) and a weaker stimulation of MAP kinase activity (7, 8).
Each of these pathways leads to activation of a specific set of
transcription factors; JNK/SAPK phosphorylates and activates
c-Jun (10, 11) and ATF-2 (12), NF-kB translocates to the nu-
cleus where it functions as a transcription factor, and MAP
kinase phosphorylates and activates Elk-1 (13, 14) and other
transcription factors.
TNFa stimulates sphingomyelinase activity, which results
in the generation of ceramide (15, 16). Treatment of cells with
the cell-permeable C2-ceramide mimics TNFa in the induction
of apoptosis (4), differentiation (15), and in the activation of a
ceramide-activated protein phosphatase activity similar to
PP2A (17, 18). A ceramide-activated protein kinase that is
proline-directed has been described, but its specific target(s) is
unknown (19). Thus, many of the biological and biochemical
effects of TNFa are mimicked by ceramide treatment, but the
molecular links between TNFa-induced ceramide production
and transcriptional activation are not clear.
EXPERIMENTAL PROCEDURES
Reagents—All reagents were obtained from Sigma unless otherwise
specified. Recombinant human TNFa (for HL-60 cells) and murine
TNFa (for L929 cells) were obtained from R&D Systems, Minneapolis,
MN. Sphingomyelinase (Bacillus cereus) was obtained from Boehringer
Mannheim. (2S,3R)-D-erythro-N-Acetylsphingosine (D-e-C2) was
prepared by acetylation of (2S,3R)-sphingosine as described (20).
DL-erythro-Dihydro-C2-ceramide was prepared by acetylation of
DL-erythro-dihydrosphingosine (20) (obtained from Sigma). Aliquots
were resuspended at 20 mM in ethanol before use. Radionucleotides
were obtained from ICN Biomedicals (Irvine, CA). [g-32P]ATP used for
in vitro kinase assays was .4000 Ci/mmol.
Tissue Culture—HL-60 cells were maintained at a density of ,1 3
106 cells/ml for less than 1 month before discarding. Cells were cultured
in RPMI 1640 (Life Technologies, Inc.) with 10% heat-inactivated fetal
bovine serum (Gemini Bioproducts, Calabasas, CA) in a humidified
atmosphere of 5% CO2, 95% air. For treatment with agonists, cells were
resuspended in serum-free medium as described (18) at a density of
250,000 cells/ml and incubated for at least 2 h before treatment. L929
fibrosarcoma cells (21) were cultured in Dulbecco’s modified Eagle’s
medium (Life Technologies, Inc.) supplemented with 5% fetal bovine
serum (Gemini).
Extract Preparation and in Vitro Kinase Assays—Whole cell extracts
were prepared as described previously (22). For assessment of JNK/
SAPK activity, 50 mg of extract was used in a solid state in vitro kinase
assay as described (23) with GST-c-Jun (10) as the substrate. For
assessment of MAP kinase activity, whole cell extracts were immuno-
precipitated with antisera to ERK2, which cross-reacts with ERK1
(SC-94, Santa Cruz Biotechnology, Santa Cruz, CA). Immune com-
plexes were collected with protein A/G-agarose (Oncogene Science,
Uniondale, NY), washed extensively, and used in an in vitro kinase
assay with 50 mM ATP (5 mCi of [g-32P]ATP), 10 mM MgCl2, 1 mM
dithiothreitol, 0.1 mM Na3VO4, 25 mM b-glycerophosphate, 10 mM
p-nitrophenyl phosphate for 20 min at 30 °C. 2 mg of GST-ElkC (a
glutathione S-transferase fusion protein containing the C terminus of
Elk-1, which contains multiple MAP kinase phosphorylation sites) was
used as substrate (14, 24). Proteins were fractionated on 12.5% SDS-
polyacrylamide gel electrophoresis and subjected to autoradiography.
Gel Mobility Shift Assays—NF-kB gel mobility shift assays were
performed as described previously (3). Antibodies used in binding as-
says (1 ml/reaction) were obtained from Santa Cruz Biotechnology.
Plasmids and Transfection Analysis—Transient transfection of L929
cells was performed by calcium phosphate coprecipitation as described
previously (25). Jun-luciferase consists of 21.1 to 1740 of human c-jun
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(26) linked to luciferase. Gal-ElkC (13) is cotransfected with 5 3 Gal-
luciferase as described (25). (KB)3-luciferase consists of three consen-
sus NF-kB sites (27) linked to luciferase. Luciferase assays were per-
formed as previously described (28).
Northern Blot Analysis—Total RNA was prepared from HL-60 cells
and electrophoresed as described previously (29). After blotting to ni-
trocellulose, the RNA was probed with a HindIII-PstI fragment of
human c-jun (30) labeled by random priming (Stratagene, San Diego,
CA) with [a-32P]dCTP (3000 Ci/mmol, ICN, Irvine, CA). Final wash
stringency was 0.1 3 SSC, 0.1% SDS at 55 °C. The blot was stripped
and reprobed with a glyceraldehyde-phosphate dehydrogenase cDNA
probe (pHcGAP, ATCC 57090) to assess sample loading.
RESULTS AND DISCUSSION
We investigated the role of ceramide in TNFa-stimulated
signal transduction by comparing the effects of TNFa, sphin-
gomyelinase, and C2-ceramide on JNK/SAPK activity, NFkB
activity, and MAP kinase activity. Exogenous bacterial sphin-
gomyelinase catalyzes the hydrolysis of cell membrane sphin-
gomyelin and the formation of ceramide when added to intact
HL-60 human myelocytic leukemia cells (31, 32). Treatment of
cells with exogenous sphingomyelinase potently activates JNK/
SAPK activity, while equivalent amounts of the lipases phos-
pholipase C, phospholipase A2, or phospholipase D do not (Fig.
1A). Exogenously added C2-ceramide or TNFa stimulates JNK/
SAPK activity in HL-60 cells to comparable levels (Fig. 1A).
The activation of JNK/SAPK activity by C2-ceramide is first
detected in cell extracts after 10 min (Fig. 1B). In contrast to
agents that transiently stimulate JNK/SAPK activity, such as
epidermal growth factor and phorbol esters (8), ceramide elicits
a prolonged activation (more than 2-fold over background lev-
els) at least 2 h after stimulation. The kinetics of JNK/SAPK
activation by ceramide parallel those of TNFa stimulation
(data not shown and Ref. 8).
Increases in JNK/SAPK activity are observed at C2-ceramide
concentrations of 1 mM and above (Fig. 1C). 5 mM C2-ceramide
stimulates JNK/SAPK activity 2.7-fold over untreated cell
levels (average of seven experiments), while TNFa (10 ng/ml)
stimulates JNK activity 2.8-fold (average of four experiments).
Uptake of C2-ceramide applied at 3 mM (16, 20) results in an
intracellular C2-ceramide concentration that is equimolar to
the concentration of ceramides generated endogenously follow-
ing cell treatment with TNFa (15).
Because C2-ceramide is an amphiphilic lipid analog that may
have nonspecific activities, it was important to establish the
specificity of its activation of JNK/SAPK, a family of kinases
activated by a wide variety of stress stimuli (7). DL-erythro-
dihydro-C2-ceramide is a close structural analog of C2-ceram-
ide lacking the trans-unsaturated bond in the sphingosine moi-
ety. Previous studies (20) demonstrated that the uptake and
metabolism of radiolabeled C2-ceramide and dihydro-C2-cer-
amide are similar. DL-erythro-dihydro-C2-ceramide fails to ac-
tivate JNK/SAPK activity (Fig. 1C, lane 8). Therefore, the
effects of C2-ceramide on JNK/SAPK are specific and suggest a
specific interaction of ceramide with a component of the JNK/
SAPK pathway.
The effect of ceramide on the induction of NFkB activity is
unresolved, in that ceramide treatment of intact cells induces
binding activity in one report (31) but not others (3, 33, 34).
TNFa potently stimulated NF-kB DNA binding activity (Fig.
2A, lane 7), with the predominant form of NFkB consisting of
p65/p50 heterodimers (Fig. 2B, lane 3). However, treatment
with bacterial sphingomyelinase (Fig. 2A, lanes 5 and 6) or
C2-ceramide (Fig. 2A, lanes 2–4) failed to induce NFkB binding
activity.
TNFa is a weak inducer of MAP kinase (ERK1 and ERK2)
activity relative to its induction of JNK/SAPK or relative to the
induction of MAP kinases by growth factors such as epidermal
growth factor (7, 8). In HL-60 cells, high concentrations of
TNFa weakly activate MAP kinase activity using recombinant
GST-Elk activation domain as a substrate in an immune com-
plex kinase assay (1.5-fold over unstimulated levels) (Fig. 3,
lane 5). As reported elsewhere (35), high concentrations of
exogenous sphingomyelinase activate MAP kinase activity
(Fig. 3, lane 7). However, treatment of cells with C2-ceramide
almost completely attenuates basal MAP kinase activity in a
concentration-dependent manner (Fig. 3, lanes 2, 3, and 8), and
FIG. 1. Stimulation of JNK/SAPK activity by sphingomyelinase
(SM) and D-e-C2-ceramide. A, HL-60 cells were cultured as described
(18) and treated with D-e-C2-ceramide (C2, 5 mM, lane 2) or ethanol only
(con, lane 1) or the enzymes indicated (300 milliunits/ml, lanes 4–7) or
vehicle (con, lane 3) or TNFa (10 ng/ml, lane 8) for 20 min. The single
prominent band visible following 10% SDS-polyacrylamide gel electro-
phoresis and autoradiography represents phosphorylated GST-c-Jun.
Equal substrate loading was confirmed in all cases by Coomassie Blue
staining of the gels prior to autoradiography. PL, phospholipase. B,
time course of JNK/SAPK induction following D-e-C2-ceramide addition
(5 mM) to HL-60 cells. The substrate (sub) for the kinase assays was
GST-cJun or GST alone as control. C, response of SAPK activity to
D-e-C2-ceramide treatment. All cells received the indicated concentra-
tion in an equal volume of ethanol or ethanol alone 5(di), 5 mM dihydro-
C2-ceramide. Extracts were prepared after 10 min of treatment. The
substrate for the kinase assay was wild-type GST-cJun (lanes 2–9) or
GST-cJun(AA) (lane 1) in which Ser-63 and Ser-73 are mutated to Ala
(10).
FIG. 2. TNFa, but not sphingomyelinase or D-e-C2-ceramide,
activates NF-kB binding activity. A, HL-60 cells were treated with
vehicle, 0.1, 1, or 10 mM C2-ceramide (lanes 1–4), or with 10 or 100
milliunits/ml sphingomyelinase (SM) (B. cereus, Boehringer Mann-
heim) (lanes 5 and 6) or recombinant TNFa (T, 10 nM, lane 7) for 30 min
prior to nuclear extract preparation and gel mobility shift analysis
using a consensus NF-kB binding site probe. ns, nonspecific shifted
complex; p50–65, heterodimeric NF-kB. B, extracts from TNFa-treated
HL-60 cells were used in binding assays, with antibodies to p50 (lane 2),
p65 (lane 3), or c-Rel (lane 4), or with a 50-fold excess of unlabeled
wild-type (wt, lane 5) or mutant NF-kB binding site (mut, lane 6)
included in the reaction. After incubation on ice for 1 h, products were
resolved on non-denaturing polyacrylamide gels. SS, supershifted
NF-kB; ns, nonspecific shifted complex (not competed by cold excess
oligonucleotide).
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this effect was not observed with dihydro-C2-ceramide-treated
cells (Fig. 3, lanes 4 and 9). Similar results are obtained using
myelin basic protein as a substrate for MAP kinase in an
immune complex kinase assay or using an in-gel MAP kinase
assay (36) with MBP incorporated into the gel (data not
shown).
The ability of ceramide to activate JNK/SAPK predicts that
ceramide would activate downstream targets of this kinase
cascade. The c-jun gene contains two non-consensus AP-1 bind-
ing sites in its promoter, which are recognized with high affin-
ity by protein complexes containing c-Jun and ATF-2 (37, 38).
The transcriptional activation domains of both c-Jun (11) and
ATF-2 (12) are phosphorylated and activated by JNK/SAPK.
TNFa, C2-ceramide, and sphingomyelinase stimulate c-jun
mRNA levels in HL-60 cells (Fig. 4A). Thus, all three agents
that stimulate JNK/SAPK activity also lead to enhanced ex-
pression of the c-jun gene. The heightened ability of sphingo-
myelinase to activate c-jun transcription may be due to its
activation of Elk-1 (Fig. 3), which can stimulate c-fos transcrip-
tion and hence increase total AP-1 activity.
To further assess the functional sequela of stimulation by
TNFa or bacterial sphingomyelinase, we measured transcrip-
tional activities with reporter gene assays in L929 fibrosar-
coma cells, which are efficiently transfected and are responsive
to TNFa (21). TNFa and sphingomyelinase are equally effec-
tive in stimulating the reporter gene driven by the c-jun pro-
moter (Jun-Luc, Fig. 4B, top panel), consistent with their stim-
ulation of JNK/SAPK activity (Fig. 1) and c-jun mRNA level
(Fig. 4A). The transcriptional activity of a fusion protein con-
sisting of the Gal4 DNA binding domain and the Elk-1 trans-
activation domain (Gal-ElkC (14); a MAP kinase substrate),
measured by a reporter plasmid containing a luciferase gene
with Gal4 binding sites (5XGal-luciferase), is activated by
sphingomyelinase and to a lesser degree by TNFa (Fig. 4B,
middle panel), in accord with their stimulation of MAP kinase
activity in vitro (Fig. 3). TNFa but not sphingomyelinase mark-
edly stimulated an NF-kB-responsive reporter gene ((KB)3-
luciferase, Fig. 4B, bottom panel), consistent with the effect of
these agents on NF-kB DNA binding activity (Fig. 2).
TNFa signals through two cell surface receptors, TNF-R1
(p55) and TNF-R2 (p75), which contain no apparent catalytic
activity and whose intracellular domains are not homologous to
characterized signaling proteins. Two proteins, TRAF1 and
TRAF2, bind to the cytoplasmic domain of TNF-R2 (39). An
unrelated protein, TRADD, binds to the TNF-R1-associated
death domain and might be involved in TNF-induced apoptosis
and NF-kB activation (40). Most of TNFa’s biological effects are
mediated by TNF-R1 (41–43), but the mechanisms by which
second messengers are recruited are unknown. Several of
TNFa’s second messengers are activated via TNF-R1, includ-
ing the activation of a sphingomyelinase, protein kinase C, and
phospholipase A2 (41). By using differences in the species spec-
ificity of TNFa (44, 45), we have found that TNFa also activates
JNK/SAPK through TNF-R1 (data not shown).
Recent studies have delineated the steps immediately up-
stream of JNK/SAPK activation (46–48), but connections be-
tween these cytoplasmic and nuclear kinases and upstream
messengers leading to their activation are unresolved. This
study demonstrates that ceramide is a link between binding of
TNFa to TNFR1 and activation of a cytoplasmic kinase cascade
that results in stimulation of JNK/SAPK activity and c-jun
expression. TNFa and C2-ceramide activate JNK/SAPK to the
same degree (Fig. 1) and stimulate activity with similar kinet-
ics in HL-60 cells. We have previously demonstrated that JNK1
(also known as SAPKg) is a major component of TNFa-acti-
vated JNK/SAPK (8). By activating JNK/SAPK, TNFa and
ceramide activate a subset of AP-1 transcription factors, such
as c-Jun and ATF-2, which in turn will preferentially induce
genes with specific non-consensus AP-1 binding sites, such as
the c-jun gene itself (Fig. 4). Therefore, this study provides
strong evidence that ceramide functions as the second
messenger in TNFa signaling resulting in the activation of
FIG. 3.MAP kinase activity is stimulated by sphingomyelinase
but not ceramide. An immune complex MAP kinase assay was per-
formed with HL-60 cell extracts prepared following cell treatment (Tx)
with the indicated agonists for 10 min (lanes 1–5) or 2 min (lanes 6–9).
C5 and C10, 5 and 10 mM D-e-C2-ceramide; C5(di), 5 mM DL-erythro-
dihydro-C2-ceramide; SM, 100 milliunits/ml Staphylococcus aureus
sphingomyelinase; TNF, 50 ng/ml recombinant human TNFa; con, con-
trol. GST-ElkC was used as the substrate. Equal substrate loading was
confirmed in all cases by Coomassie Blue staining of the gels prior to
autoradiography.
FIG. 4. Stimulation of c-jun transcriptional activity. A, c-jun
mRNA levels are increased following TNFa, sphingomyelinase, and
C2-ceramide treatment. HL-60 cells were incubated with TNFa (TNF,
20 ng/ml), sphingomyelinase (SM, 100 milliunits/ml), C2-ceramide
(CER, 10 mM), or untreated (NONE) for 1 h, and total RNA was pre-
pared followed by electrophoresis and Northern blotting. The blot was
hybridized first with a radioactively labeled human c-jun probe (upper
panel) and then with a labeled human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) probe. Blots were quantitated by phosphor
image analysis, and -fold induction of c-jun mRNA normalized to
GAPDH mRNA (FOLD) is indicated. B, activity of luciferase reporter
genes in the L929 fibrosarcoma cell line. Jun-luciferase (Luc), or 5XGal-
luciferase plus Gal-ElkC, or (KB)3-luciferase (three copies of the con-
sensus NF-kB response element linked to luciferase) was transfected
into L929 cells. Cells were then treated with TNFa (20 ng/ml) or
sphingomyelinase (100 milliunits/ml) for 5 h, and extracts were pre-
pared for determination of luciferase activity. -Fold activation repre-
sents reporter activity relative to cells treated with vehicle only. Results
from one representative experiment performed in duplicate are shown
(6S.E.). Results were consistent over at least three experiments.
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JNK/SAPK and c-jun.
TNFa is not a potent activator of MAP kinases (7, 8), and we
demonstrate here that C2-ceramide actually decreases MAP
kinase activity in HL-60 cells. Inhibition of MAP kinase activ-
ity may result from the activity of a ceramide-activated protein
phosphatase (17, 18) acting on a component of the MAP kinase
cascade. Ceramide-activated protein phosphatase is a phospha-
tase of the PP2A class, and PP2A activity on both MAP kinases
and MEKs has been described (reviewed in Ref. 49). The weak
activation of MAP kinase activity by TNFa may be the result of
ceramide-independent activation of a component (MEK or MAP
kinase itself) downstream of Raf-1 and/or by activation of pro-
tein kinase C (50).
TNFa is a potent inducer of NFkB (5, 51) (Figs. 2 and 4),
perhaps through the activation of protein kinase C z (52), and
ceramide potentiates the stimulation of NFkB by TNFa (3).
Ceramide stimulates NF-kB binding activity in permeabilized
cells, which has been attributed to the activation of an acidic
sphingomyelinase (32). However, extracts derived from intact
HL-60 cells treated with exogenous sphingomyelinase or C2-
ceramide have elevated JNK/SAPK activity but not NF-kB
DNA binding activity. Perhaps these different results reflect
the existence of separate ceramide pools, such that C2-ceram-
ide and the ceramide generated by exogenous bacterial sphin-
gomyelinase are in a different cellular compartment than the
ceramide generated by acidic sphingomyelinase.
The evidence is pointing to the existence of a novel signal
transduction pathway that may be specifically involved in the
stress response. A number of agents of systemic stress (e.g.
TNFa) and tissue injury (hypoxia, UV irradiation, and chemo-
therapeutic agents) activate both a neutral sphingomyelinase
and JNK/SAPK. This study provides a link between the sphin-
gomyelinase/ceramide pathway and the JNK/SAPK pathway
by demonstrating that ceramide functions upstream of JNK/
SAPK, resulting in activation of nuclear downstream effects.
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